 <h1>Hyaluronidase / immune globulin Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2>In Summary</h2><p><b>More frequently reported side effects include:</b> fever, nausea, and vomiting.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to hyaluronidase/immune globulin: subcutaneous solution</i></p><h3>Warning</h3><p class="blackboxWarning-title">Subcutaneous route (Kit)</p><p>Thrombosis may occur with immune globulin/recombinant human hyaluronidase in patients with or without known risk factors. Risk factors may include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Adequate hydration prior to administration is recommended.  Administer at the minimum dose and infusion rate practicable in patients at risk of thrombosis. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, hyaluronidase / immune globulin may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking hyaluronidase / immune globulin:</p><p>
<i>More common</i>
</p><ul>
<li>Fever</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of hyaluronidase / immune globulin may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Headache</li>
<li>nausea</li>
<li>red streaks on the skin</li>
<li>swelling, tenderness, or pain at the injection site</li>
<li>unusual tiredness or weakness</li>
<li>vomiting</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Itching, redness, swelling, discomfort, or pain at the infusion site</li>
</ul><p>
<!-- end subcutaneous solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to hyaluronidase / immune globulin: subcutaneous solution</i></p><h3>General</h3><p>The most common adverse events were local reactions, headache, antibody formation against recombinant human hyaluronidase (rHuPH20), fatigue, nausea, pyrexia, and vomiting.<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Local reaction (51.9%)</p>
<p><b>Frequency not reported</b>: Local pain and swelling, discomfort/pain, erythema, pruritus<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (21%), fatigue (11.1%)</p>
<p><b>Postmarketing reports</b>: Transient ischemic attack, tremor, burning sensation, cerebrovascular accident, coma, seizures, loss of consciousness<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Antibodies to recombinant human hyaluronidase (18%)<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Systemic adverse reaction (67.9%)</p>
<p><b>Common</b> (1% to 10%): Pyrexia</p>
<p><b>Frequency not reported</b>: Fever, back injury, transient swelling from abdominal infusion site to genitalia</p>
<p><b>Postmarketing reports</b>: Edema, rigors<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Nausea, vomiting</p>
<p><b>Postmarketing reports</b>: Abdominal pain<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Frequency not reported</b>: Acute intravascular hemolysis</p>
<p><b>Postmarketing reports</b>: Leukopenia, pancytopenia<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Frequency not reported</b>: Acute renal dysfunction/failure<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Postmarketing reports</b>: Hypotension, hypertension, myocardial infarction, chest pain, cardiac arrest, vascular collapse<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Postmarketing reports</b>: Pulmonary edema, dyspnea, oxygen saturation decreased, cyanosis, hypoxemia, bronchospasm, apnea, acute respiratory distress syndrome (ARDS)<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Postmarketing reports</b>: Hyperhidrosis, allergic dermatitis, bullous dermatitis, epidermolysis, erythema multiforme, Stevens-Johnson Syndrome<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Postmarketing reports</b>: Hepatic dysfunction<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Postmarketing reports</b>: Anxiety, insomnia<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Postmarketing reports</b>: Back pain<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Hyqvia (hyaluronidase-immune globulin)." Baxter Healthcare Corporation, Deerfield, IL. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about hyaluronidase / immune globulin</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>Drug class: immune globulins</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Immune globulin and hyaluronidase Subcutaneous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Hyqvia</dd></dl>
<h3>Professional resources</h3>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Primary Immunodeficiency Syndrome</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to hyaluronidase / immune globulin: subcutaneous solution</i></p><h3>General</h3><p>The most common adverse events were local reactions, headache, antibody formation against recombinant human hyaluronidase (rHuPH20), fatigue, nausea, pyrexia, and vomiting.<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Local reaction (51.9%)</p><p><b>Frequency not reported</b>: Local pain and swelling, discomfort/pain, erythema, pruritus<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (21%), fatigue (11.1%)</p><p><b>Postmarketing reports</b>: Transient ischemic attack, tremor, burning sensation, cerebrovascular accident, coma, seizures, loss of consciousness<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Antibodies to recombinant human hyaluronidase (18%)<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Systemic adverse reaction (67.9%)</p><p><b>Common</b> (1% to 10%): Pyrexia</p><p><b>Frequency not reported</b>: Fever, back injury, transient swelling from abdominal infusion site to genitalia</p><p><b>Postmarketing reports</b>: Edema, rigors<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Nausea, vomiting</p><p><b>Postmarketing reports</b>: Abdominal pain<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Frequency not reported</b>: Acute intravascular hemolysis</p><p><b>Postmarketing reports</b>: Leukopenia, pancytopenia<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Frequency not reported</b>: Acute renal dysfunction/failure<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Postmarketing reports</b>: Hypotension, hypertension, myocardial infarction, chest pain, cardiac arrest, vascular collapse<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Postmarketing reports</b>: Pulmonary edema, dyspnea, oxygen saturation decreased, cyanosis, hypoxemia, bronchospasm, apnea, acute respiratory distress syndrome (ARDS)<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Postmarketing reports</b>: Hyperhidrosis, allergic dermatitis, bullous dermatitis, epidermolysis, erythema multiforme, Stevens-Johnson Syndrome<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Postmarketing reports</b>: Hepatic dysfunction<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Postmarketing reports</b>: Anxiety, insomnia<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Postmarketing reports</b>: Back pain<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Hyqvia (hyaluronidase-immune globulin)." Baxter Healthcare Corporation, Deerfield, IL. </p><h2>More about hyaluronidase / immune globulin</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>Drug class: immune globulins</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Immune globulin and hyaluronidase Subcutaneous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Primary Immunodeficiency Syndrome</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>